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The DR antigens  are a  group of human histocompatibility antigens which have 
attracted great interest because of their role in cell-cell interactions (1). These antigens 
have  a  two-chain structure consisting of noncovalently associated  glycoproteins of 
34,000  and  29,000  mol  wt  (2-5)  and  exhibit  considerable  amino  acid  sequence 
homology at the NH2-terminal end with murine Ia E/C subregion antigens (6). Like 
their murine analogs, DR antigens have a restricted tissue distribution compared with 
the HLA-A, B, and C  antigens because they are mainly expressed by cells associated 
with immune functions (7). 
Some adenocarcinoma cells of mice have been reported to produce Ia antigens as 
indicated by their ability to elicit anti-Ia alloantibodies (8). If so, human tumor cells 
of nonlymphoid origin, in contrast to their nonmalignant counterparts, may express 
DR antigens.  Because these antigens are involved in immune phenomena and have 
been reported to control cell proliferation (9), their detection on malignant cells may 
relate to the disordered proliferation of tumor cells and aid our understanding of their 
mechanism(s) of escape from immune destruction. 
Cultured human melanoma cells were studied for the presence of DR antigens to 
test  the  hypothesis  that  malignant  cells  of nonlymphoid  origin  can  express  DR 
antigens. The melanoma system was selected because melanocytes have been reported 
to  lack  DR  antigens  (10,  11),  and  the  cellular and  humoral  immune  reactions  to 
melanoma-associated antigens have been suggested to affect the clinical course of this 
disease  (12).  Results to be presented indicate that  (a) some melanoma cell lines can 
express DR antigens;  (b) the DR antigens on cultured melanoma cells are immuno- 
logically functional as they can bind DR xeno- and alloantibodies and can elicit DR 
antibodies in a xenogeneic combination; and (c) DR antigens on cultured melanoma 
cells have a  two-chain structure like those on B-lymphoid cells, however, the DR fl- 
chain derived from melanoma cells appears to have a slightly lower molecular weight 
than the DR fl-chain derived from the Victor B-lymphoid cell line. 
Materials and Methods 
Cultured Human Cells.  The lymphoblastoid cell lines Victor and WI-L2, used in this study, 
have been described previously in terms of sources, cell surface antigens, and receptors (13,  14). 
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The following 11 cultured human melanoma cell lines were used in this study: 1) Colo 38, C:olo 
53, C:olo 55,  MI4, M16,  M21,  MS1,  BW-5, Allen, Danison, and Vega.  Background on the 
origin of the Colo cell series and the M series (15) and the BW-5 cell line (16) is available in the 
literature. The cell lines Allen, Danison, and Vega, which were established by primary explant 
from surgical specimens obtained from three melanoma patients, were a gift from Dr. Y. H. 
Pilch, Department of Surgery, University of California, San Diego, Calif. 
Allo- and  Xenoantisera  to  Cell  Surface Markers.  DR alloantisera were obtained from parous 
women whose  sera  lacked  cytotoxic  activity to  the  peripheral  lymphocytes of at  least  80 
unrelated donors (17). The specificity of these DR alloantisera was determined by testing with 
a panel of DR-typed B-lymphoid cells (14). The DR alloantibody eluate (78-E8) was obtained 
by acid elution (18) from 1 ×  109 Daudi cells incubated with 50 ml of an HLA alloantiserum. 
This  eluate  was  cytotoxic  to  cultured  B-lymphoid cells  and  enriched  preparations  of B- 
peripheral  lymphocytes but  not  to  T  lymphocytes from  10  unrelated donors  (prepared  as 
previously published) (19). Furthermore, 78-E8 did not react with the cultured T-lymphoid cell 
lines Molt 4 and 1301 in an indirect rosette microassay,  x In indirect immune precipitation, 78- 
E8 reacted with antigenic structures of 34,000 and 29,000 mol wt which are characteristic of 
the a- and fl-chains of DR antigens (2-5). 
A specific xenoantiserum to DR antigens (rabbit 8612) was produced as previously described.  2 
Briefly,  an anti-Daudi cell  xenoantiserum which was made specific  for  B-lymphoid cells  by 
absorption with  1301 and Molt 4 T-cell lines was reacted with Staphylococcus aureus, C:owan I 
strain (SAC:I)  3 (c:albiochem-Behring Corp., American Hoechst Corp., San Diego,  Calif.) The 
anti-DR-loaded SAC:I preparation was then mixed with an NP-40 extract of B-lymphoid cells 
(e.g.  RPMI 4098)  to bind DR  antigens. These SAC:I-antibody-DR antigen complexes were 
injected into rabbits. The resulting antisera were shown by serological and immunochemical 
tests to react specifically with the same antigenic structures detected by DR alloantisera.  2 
Xenoantiserum 3634  which  contained antibodies to  the  heavy chain of HLA-A and  B 
antigens and to DR antigens (20) was obtained from a rabbit immunized with histocompati- 
bility antigens solubilized from  cultured WI-L2  lymphoid cells  and  partially purified  by 
uhracentrifugal flotation in KBr (21). This xenoantiserum has been used successfully to purify 
DR antigens for amino acid sequence analysis (6). 
Anti-human  fi~-microglobulin  (fl~o/z) xenoantiserum  was from a cow immunized  with purified 
urinary fi2-/z. Anti-Moh 4 antiserum was from a rabbit (6521) immunized with Molt 4 cells. 
Rabbits 7428 and 7617 were primed and boosted with intramuscular injections of 3-5 ×  10  ~ 
BW-5 and M 16 melanoma cells, respectively.  The cells had been washed in phosphate-buffered 
saline and mixed with 300/zls of Mylantha (Stuart Pharmaceuticals, Wilmington, Del.)  for 
each injection. 
Serological Tests.  The indirect rosette microassay was  performed as described.  1 Briefly,  20 
/zl of a cell suspension (5  ×  l0  s cells/ml) was mixed with 20/~1 of an appropriate dilution of 
antisera in microtiter plates. This mixture was incubated at 4°C: for 60 min and then washed 
six  times with minimum essential medium. 20/zls of a  2% suspension of sheep erythrocytes 
coupled with purified antibody to either rabbit or human gamma globulin was added. The 
cells were pelleted, resuspended, and stained with toluidine blue (0.1% in saline), after which 
the  percentage  of rosettes  was  determined by counting 200  cells.  The  cytotoxic  test  with 
melanoma cells  (22) and  cultured  human lymphoid cells  (23) and  the  lysostrip  test  (24) 
(resistance to complement-dependent lysis after redistribution of antigens with corresponding 
antibodies) were performed as described. 
Indirect  Immunoprecipitation  and  Sodium Dodecyl Sulfate  (SDS)-Polyacrylamide  Gel  Electrophoresis 
(PAGE).  Indirect immunoprecipitation was performed following the method of C:ullen and 
Schwartz (25) with minor modifications described in detail elsewhere  (26). Briefly, lentil-leetin- 
Indiveri, F., B. S. Wilson,  M. A. Pellegrino,  and S. Ferrone. 1978. Detection of human histocompatibility 
antigens with an indirect rosette microassay.J. Irnmunol. In press. 
Wilson, B. S., F. Indiveri, M. A. Pellegrino, and S. Ferrone. 1978. Production and characterization of 
DR xenoantisera: use for detection of serum DR antigens. Manuscript submitted for publication. 
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FIG.  1.  Detection  of DR  antigens  on  cultured  human  melanoma  cells by  an  indirect  rosette 
microassay. Eight melanoma cell lines, BW-5 (O), M14 (m), M16 (A), and others (Colo 53, Colo 55, 
M21, M51, and Allen) were treated with either anti-DR xenoantiserum 8612 (1:40 dilution), normal 
rabbit serum (NRS)  (1:40 dilution), anti-DR alloantibody eluate 78-E8  (1:10 dilution) or normal 
human  serum  (NHS)  (1:10  dilution)  and were then rosetted with either anti-rabbit  Ig or anti- 
human Ig-coated sheep erythrocytes. 
purified glycoproteins from 3H-leucine-labeled  cells  (25) were  reacted with antibody-loaded 
SACI. The labeled glycoproteins were eluted from the SACI by boiling with 2% 2-mercapto- 
ethanol and 2% SDS and then electrophoresed on SDS-PAGE as described  by Laemmli (27). 
The gels were cut into l-ram slices and analyzed by liquid scintillation counting. 
Results 
Serological Detection of DR  Antigens on  Cultured Human Melanoma  Cells by  Indirect 
Rosetting.  Of the  11 melanoma cell lines available in our laboratory, 3 (BW-5, M 14, 
M16) grow as monolayers and the remaining 8 grow as suspension cultures. When the 
11  melanoma cell  lines  to  be  tested  for  DR  antigens  were  treated  with  a  specific 
xenoantiserum  (8612)  to common structures  of DR  antigens  in  an  indirect  rosette 
microassay, only the three cell lines BW-5, M 14, and M 16 consistently formed rosettes 
with the DR xenoantiserum (Fig.  1). In addition, the melanoma lines BW-5 and M 16 
reacted in the indirect rosette microassay with the antibody eluate 78-E8, an alloan- 
tibody preparation which  is  highly  specific for DR antigens.  The cell  line Colo 38 
varied  in  its  reactivity with  the  DR  xenoantiserum  8612  and  the  eluate  78-E8  in 
separate  experiments,  the  percentage  of rosettes  ranging  from 0  to  30%  (data  not 
shown); the remaining seven cell lines, only five of which are shown in Fig.  1, did not 
react with  the  DR xeno- and alloantibodies.  Because the  monolayer cell lines were 
harvested with trypsin, it was not known whether trypsin treatment had increased the 
expression of DR antigens on these cell lines. However, monolayer cell lines harvested 
wtih  0.2  M  EDTA  were  as  reactive  as  trypsin-treated  cells  to  DR  antibodies. 
Furthermore, treatment of suspension melanoma cell lines with trypsin or EDTA did 
not increase their reactivities with the DR antibodies  (data not shown). 
The three melanoma cell lines BW-5, M14, and M16 were compared with cultured 
B-lymphoid cell lines for reactivity with the DR xenoantiserum 8612  in the indirect 
rosette microassay. The titer of the xenoantiserum was about 1/160 for the melanoma 
cells and about  1/8,000  for a representative lymphoid cell line, RPMI 4098  (Fig. 2). 
These data suggest that expression of DR antigens is much lower on melanoma cells 
than on B-lymphoid cells; a low level of expression of DR antigens on melanoma cells 
would  also  explain  why  we  were  unable  to  obtain  consistent  results  when  the 
melanoma cell lines BW-5, M14, and M16 were reacted with the xenoantisera 8612 
and rabbit complement in the microcytotoxic test (data not shown). 
Detection of DR-Specific Xenoantibodies in Anti-Melanoma Antisera.  The melanoma lines 
BW-5  and  M16,  which  react  with  DR  allo-  and  xenoantisera,  were  injected  into WILSON,  INDIVERI, PELLEGRINO, AND  FERRONE 
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FIG. 2.  Titration  of the anti-DR  xenoantiserum 8612 with a B-lymphoid cell line RPMI 4098 
(O) and with cultured  melanoma cells BW-5 (Q), MI4 (.), and M16 (&) in an indirect rosette 
microassay. 
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TABLE I 
Susceptibility of WI-L2 Cells to Complement-Dependent Lysis after Redistribution (Stripping)  of Cellular 
Antigens with Xenoantisera to Melanoma Cells 
Stripping* antiserum 
Susceptibility to lysis 
Anti-HLA-A2  Anti-DRw4  Anti-Molt 4(6521) 
Rabbit anti-BW-5  -  -  + 
Rabbit anti-M 16  -  -  + 
Bovine anti-~2-#  -  +  + 
* WI-L2 cells were treated with antiserum for 30 min at 25°C and then washed and incubated with goat 
anti-rabbit  Ig or anti-bovine Ig antiserum for 1 h at 37°C to induce redistribution of cellular antigens. 
rabbits  to  determine  whether  the  DR  antigens  derived  from  melanoma  cells  are 
immunogenic.  The  resulting  antisera  were  then  analyzed  for  reactivity  with  DR 
antigens in lysostrip and indirect immunoprecipitation experiments because both tests 
detect  DR  xenoantibodies  even  though  heterogeneous  populations  of antibodies  to 
other cell  surface  markers  are  present.  In this  way, xenoantisera  to melanoma  cells 
could be analyzed for their content of DR antibodies without prior absorption. 
In the lysostrip experiments,  WI-L2 lymphoid cells  (HLA-A1, A2, B5, B17, DRw, 
4, 7) were first treated with xenoantisera to melanoma cells BW-5 (7428), M 16 (7617), 
and anti-fl2-/.t.  After redistribution  of antigens  in cell  membrane  (capping),  the cells 
were tested with anti-HLA-A2, anti-DRw4 alloantisera and with anti-Molt 4 xenoan- 
tiserum  (6521)  in the cytotoxic text.  As a  result, cells pretreated  with  7428 and  7617 
xenoantisera  resisted  complement-dependent  lysis  mediated  by  anti-HLA-A2  and 
DRw4 alloantisera but were still susceptible to lysis mediated by 6521 xenoantiserum 
(Table I). This resistance of WI-L2 cells to lysis by alloantisera after stripping surface 
antigens with anti-melanoma antisera was specific, because WI-L2 cells treated with 
xenoantiserum  to f12-# remained  susceptible  to lysis by anti-DR  alloantiserum  and 
6521 antiserum  (Table I). 
To characterize  the molecules reactive with  anti-melanoma  antisera,  we used  the 
indirect immunoprecipitation technique and reacted 7428 and 7617 xenoantisera with 
aH-leucine-labeled  glycoproteins purified  from the Victor B-lymphoid cell line.  The 
SDS-PAGE analysis of these immunoprecipitates showed that the melanoma xenoan- 
tiserum 7428 reacted with antigenic structures having mol wt ofg0,000, 45,000, 34,000 662  MELANOMA  DR  ANTIGENS 
HSA  OA  CA  HSA  OA  CA 
'F  'F  i' 
lP  20  30  40  50  I0  20  30  4'0  5'0 
Milration  Oistanco min 
FIG.  3.  Immunoprecipitation and  SDS-PAGE  analysis  of anti-melanoma  (7428)  and  anti-B- 
lymphoid (3634) cell xenoantisera reactive with B-cell (Victor)  glycoproteins.  Xenoantiserum 3634 
unadsorbed (panel  A) and adsorbed with 1301 cells (panel  C), 7428 antiserum unadsorbed (panel 
B), and adsorbed with  1301 cells (panel  D) were first bound to SACI and then reacted with aH- 
leucine-labeled Victor glycoprotein.  Immunoprecipitated glycoproteins  were electrophoresed under 
reducing conditions on 10% SDS-PAGE.  Human serum albumin (HSA, 65,000 mol wt), ovalbumin 
(Ov, 44,000 mol wt) and carbonic anhydrase (CA, 29,000 mol wt) were run on companion gels as 
standards. 
and 29,000  (Fig. 3).  Similar results were also obtained using 7617 (data not shown). 
The  latter three components also  immunoprecipitated by the xenoantiserum  3634 
(produced  against  high  density  lipoprotein-associated  histocompatibility antigens) 
corresponded to the allotypic heavy chain of HLA-A, B alloantigens and the a-chain 
and fl-chain of the DR antigen molecule, respectively. Absorption of 7428 xenoantis- 
erum  with  the  lymphoid  cells  1301,  which  do  not  express DR  antigens,  removed 
antibodies to the 90,000 and 45,000 mol wt components but not to the 34,000 and 
29,000 tool wt components. Similar results, which are shown for comparative purposes, 
were also obtained with the xenoantiserum 3634. Thus, xenoantisera to the melanoma 
cells BW-5 and  M16 contained antibodies to 34,000- and  29,000-mol wt  structures 
which are characteristic of the a- and fl-chains of DR-antigen molecules. 
Sequential immunodepletions were then performed to establish whether the 34,000 
and 29,000 tool wt B-lymphoid cell components detected by anti-melanoma antisera 
are in fact DR antigens. For this purpose, antibody-loaded SACI were used to remove 
various  components  from  a  labeled  glycoprotein preparation  of Victor  cells.  3H- 
leucine-labeled glycoproteins were divided into two aliquots; one aliquot was treated 
with 7428-loaded SACI and the other with normal rabbit serum-loaded SACI. After 
three successive depletions,  the  remaining  glycoproteins were reacted with  the xe- 
noantiserum  3634,  specific  for  HLA-A,  B,  and  DR  antigens.  Antigen-antibody 
complexes in the mixture were precipitated with SACI, and labeled antigens eluted 
from the precipitates were analyzed by SDS-PAGE.  As the results shown in Fig.  4 
indicate,  7428  (anti-BW-5)  antibodies specifically depleted the Victor glycoprotein 
preparation of almost all the DR antigens reactive with the DR xenoantiserum 3634. 
These  results  indicate  that  anti-melanoma  antisera  react  with  the  DR  antigens WILSON, INDIVERI, PELLEGRINO, AND FERRONE  663 
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Fie. 4.  Reactivityaof  DR xenoantisera with B-cell glycoproteins  immunodepleted with anti-BW-5 
(7428) antiserum.  H-leucine-labeled glycoprotein from Victor cells was immunodepleted three 
times with SACI loaded with either 7428 antiserum (---) or normal rabbit serum (  ). The 
remaining glycoproteins  were precipitated by xenoantiserum 3634 bound to SACI  and analyzed by 
SDS-PAGE (under reducing conditions on 10% gels). 
synthesized by B-lymphoid cells.  In contrast,  neither  SACI-absorbed normal rabbit 
serum nor antiserum to Molt 4 cells  (6521)  (28) reduced the amount of DR antigens 
precipitated by the antiserum 3634 (Fig.  4). 
Immunochemical Characterization of Melanoma  DR Antigens.  The melanoma cell  lines 
BW-5 and ColD 38 were both used in these experiments because one cell line grows as 
a monolayer and the other as a suspension culture. The labeled glycoproteins purified 
from these cells  were reacted with the xenoantiserum 8612 and with the DR alloan- 
tibody eluate  78-E8. The antigen-antibody complexes were precipitated with SACI, 
eluted, and the labeled immunoprecipitates were then electrophoresed on SDS-PAGE 
gels.  Immunoprecipitation of ColD 38 glycoproteins with 8612 detected two compo- 
nents; one component was ~34,000 mol wt and the other was ~27,000 mol wt. This 
electrophoretic pattern is shown and compared to that of Victor DR antigens in Fig. 
5. The specificity of this immunoprecipitation reaction was indicated by the absence 
of any reactivity when ColD  38 glycoprotein was reacted with normal rabbit  serum 
(Fig.  6). The fact that the two peaks detected by 8612 antiserum were the a- and fl- 
chain of the DR molecule from melanoma cells  is substantiated by an experiment in 
which  identical  34,000  and  27,000  mol  wt  components  were  immunoprecipitated 
from ColD 38 glycoproteins with the highly specific anti-DR alloantibody eluate  78- 
E8 (Fig.  7). These results were repeated and confirmed when the melanoma cell line 
BW-5 was substituted for Cold 38 (data not shown). 
Xenoantiserum  3634, which contain antibodies  to DR antigens and  to the  HLA 
heavy chain  was  used  to  compare  the  expression  of DR  antigens  to  that  of HLA 
antigens on both melanoma cells  and  B-lymphoid cells.  With  3634,  the  amount of 
radioactivity precipitated from a ColD 38 glycoprotein preparation by DR antibodies 
was  much  lower  than  that  precipitated  by  HLA heavy chain  antibodies  (Fig.  6), 
whereas, the opposite result was obtained with Victor B-cell  glycoprotein (Fig.  4). 664  MELANOMA  DR  ANTIGENS 
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Fro.  5.  Detection of melanoma DR antigens with a DR xenoantlserum. SACI loaded with anti- 
DR xenoantiserum 8612 were reacted  with aH-leucine-labeled  glycoprotein  from Victor cells (A) 
and Colo 38 cells (B). The immune complexes were eluted and electrophoresed  on SDS-PAGE as 
described  in Fig. 4. 
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Fro. 6.  Immunoprecipitation and SDS-PAGE  analysis of melanoma glycoproteins  reactive with 
DR xenoantiserum 3634 and normal rabbit serum. DR xenoantiserum 3634 (0"'"-0) and normal 
rabbit serum (- - -) bound to SACI were reacted with SH-leucine-labeled glycoprotein from Colo 38 
cells. The immune complexes were eluted and run on SDS-PAGE as described in Fig. 3. 
Discussion 
Several lines of evidence indicate that cultured human  melanoma cells can express 
DR antigens: (a) cultured melanoma cells reacted with specific DR allo- and xenoan- 
tibodies in an indirect rosette assay;  (3) melanoma cells synthesize antigenic molecules 
with molecular structures similar to the DR antigens synthesized by B-lymphoid cells; 
(c)  immunization  of rabbits with  melanoma  cell  lines serologically positive  for  DR 
antigens (BW-5 and M 16) resulted in the production of antibodies showing serological 
specificity  for  DR  antigens.  Immunochemica[  studies  with  these  anti-melanoma 
antisera  indicated  that  they  reacted  with  the  same  molecules of 34,000  and  29,000 
mol  wt  detected  by  DR  xenoantiserum  3634;  in  previous  studies  these  molecules, 
reactive with 3634, were found to exhibit considerable amino acid sequence homology 
at the amino terminal end with DR antigens purified by a  conventional biochemical WILSON,  INDIVERI,  PELLEGRINO,  AND  FERRONE 
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FIG.  7.  Immunoehemical detection  of melanoma  DR  antigen  with  an  anti-DR  alloantibody 
eluate. Anti-DR alloantibody eluate  78-E8, bound to SACI, was reacted with 3H-leueine-labeled 
glycoproteins from Colo 38. The immune complexes were eluted and run on SDS-PAGE as described 
in Fig. 3. 
approach  (29)  and  with  the  murine  Ia  E/C  subregion  antigens  (6).  These  data 
combined  overrule  the  possibility  that  the  reaction  of melanoma  cells  with  DR 
antisera was actually a result of contaminating anti-viral antibodies or cross-reactive 
antigens. These two alternatives were previously offered to account for the unexpected 
reactions of histocompatibility alloantisera with some human and murine tumor cells 
(30, 31). 
Human  melanoma  cells  seem  to  express  a  smaller  amount  of DR  antigens  as 
compared with B-lymphoid cells because:  (a) the endpoint titer of the DR xenoanti- 
serum  (8612)  with melanoma cell lines was  many fold lower than  the titer with a 
typical B-lymphoid cell line (RPMI 4098);  (b) approximately six times more labeled 
melanoma glycoprotein than B-lymphoid glycoprotein was required to detect even 
minimal amounts of DR molecules with anti-DR xenoantiserum by indirect immune- 
precipitation and SDS-PAGE; (c) xenoantiserum 3634 which reacts very strongly with 
DR antigens but only weakly with HLA-A, B antigens from B-lymphoid cells, reacted 
better with HLA-A and B than with DR antigens from melanoma cells. Consequently, 
either  the  DR  antigens  from  melanoma  cells  are  synthesized  in  relatively  small 
amounts or the DR xenoantisera used in this study cross-reacted weakly with these 
melanoma-derived  DR  antigens  because  these  antisera  (8612,  3634)  were  elicited 
against DR antigens from B-lymphoid cells. We favor the former alternative, because 
the  DR  antibodies  present  in  xenoantisera  to  melanoma  cells  also  reacted  more 
strongly with DR antigens of B-lymphoid cells than with DR antigens from melanoma 
cells. 
The fact that some melanoma cell lines are DR positive and others are DR negative 
may reflect the development of melanoma cells from different precursors. Alterna- 
tively, if one accepts the hypothesis that DR antigens are differentiation antigens and 
are expressed at  various stages  of maturation,  then  the  variable expression of DR 
antigens by different melanoma cell lines may reflect the stage of differentiation at 
which the melanocyte becomes a tumor cell. Furthermore, the variable expression of 
DR antigens by different melanoma cell lines may be quantitative, not qualitative, in 
the sense that DR-negative melanoma cells express DR antigens but at a density too 
low to be detected by our serologic techniques. In fact, some of the serologically DR- 
negative melanoma cells (e.g. Colo 38 and M51) were able to elicit anti-DR antibodies 
after injection into rabbits (B. S. Wilson and L. E. Walker, unpublished observations). 
These data are similar to findings with some murine mammary adenocarcinoma cells 666  MELANOMA  DR  ANTIGENS 
which can elicit production of Ia alloantibodies even though they lack serologically 
detectable Ia antigens (8). Thus, in view of the strong immunogenicity of DR antigens, 
other research may reveal that these antigens exist on all melanoma cells and possibly 
on other tumor cells of nonlymphoid origin. 
SDS-PAGE  analysis  of the  melanoma  DR  antigen  indicates  that  its  a-chain  is 
~34,000 mol wt and its/3-chain is ~27,000 mol wt or slightly less than the/~-chain of 
the Victor B-lymphoid cell line (29,000 mol wt). This lower molecular weight of the 
DR/~-chain derived from melanoma cells may result either from proteolytic cleavage 
or from differences in carbohydrate content between/3-chains derived from lymphoid 
and  melanoma  cells,  respectively.  This  notion  is  based  on  the  observation  that 
carbohydrate content  affects migration  rates  of glycoproteins on  SDS-PAGE  (32). 
Besides  clarifying  these  structural  differences,  further  studies  will  be  directed  at 
determining whether DR  antigens on melanoma and  B-lymphoid cells differ func- 
tionally, e.g. in mixed lymphocyte reactions. 
The  observation  that  melanoma  cells  can  produce  DR  antigens  whereas  their 
normal counterparts  (melanocytes) do not  (10,  11), raises some important questions 
about how these new antigens develop and their relationship, if any, to the malignant 
state of the tumor cell. The expression of DR antigens by melanoma cells might result 
from (a) derepression or activation of gene(s) coding for DR antigens,  (b) repression 
of genes coding for substances  masking  DR  antigens,  or  (c)  changes in  the  rate of 
synthesis  and/or  shedding  of DR  antigens.  Because  this  study  involved cultured 
melanoma cells, we are not yet certain whether in vivo melanoma cells express DR 
antigens.  If so, the expression of DR antigens may relate to the immunogenicity of 
melanoma-associated  antigens.  For example,  in  experiments with  guinea  pigs,  the 
presence of Ia antigens was necessary for the immunogenicity of leukemia-associated 
antigens (33).  Studies are currently in progress to test this hypothesis further. 
Besides these theoretical considerations, the expression of DR antigens by melanoma 
cells  requires  consideration  when  melanoma  cells  are  typed  for HLA,  -A,  and  -B 
antigens, because the vast majority of HLA-, A-, and B-typing sera are contaminated 
with antibodies to DR antigens. These contaminant antibodies may cause unexpected 
reactions as was previously found for the HLA-A and B typing of B-lymphoid cells 
(7).  Finally,  the  detection  of DR  antigens  on  melanoma  cells  may  improve  the 
classification of melanoma as a  disease and bear on the clinical association between 
the course of disease and/or response to therapy. 
Summary 
11  cultured  human  melanoma  cell  lines  were  tested  for  the  expression  of DR 
antigens  by using specific allo- and  xenoantisera in  an  indirect rosette microassay. 
Four of these melanoma cell lines expressed DR antigens, but in lower amounts than 
expressed on cultured human B-lymphoid cells. Rabbits injected with the DR-positive 
melanoma cells produced antibodies that were serologically and immunochemically 
reactive  with  B-cell-derived  DR  antigens.  Immunochemical  studies  indicate  that 
melanoma  cell-derived DR  antigens  have  a  two-chain  structure  with  34,000  and 
27,000 mol wt components. The melanoma cell-derived DR/3-chain at 27,000 mol wt 
is slightly smaller than that of the Victor cell DR ~-chain whose mol wt is 29,000. 
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